Zomedica Corp. Annual Report - A Clearer Look at Their Year

Curious about Zomedica Corp.'s performance over the past year? This summary breaks down their annual report into straightforward language, highlighting key insights for investors. We'll explore their business, financial results, risks, and future plans, offering a clear picture of their current standing and what lies ahead.

This guide covers Zomedica's performance for the financial year that ended on December 31, 2024.

1. Business Overview

Zomedica is an animal health company that develops and sells innovative diagnostic and therapeutic products for veterinarians. Their strategy involves expanding their product range through both acquisitions and internal development. For example, in 2022, they acquired Assisi Animal Health and Revo Squared, followed by Brisby Inc. in April 2023. These acquisitions brought products like the SmartPetPad and IntelligentPetPad – therapeutic pads designed to help with animal recovery and well-being – into their offerings.

Zomedica operates in an animal health market shaped by several key trends:

• Increasing pet ownership
• Greater spending on pet healthcare
• Technological advancements in veterinary medicine

Zomedica aims to leverage these trends with its product offerings.

2. Financial Performance

Let's look at Zomedica's financial results for the fiscal year ending December 31, 2024:

• Total Revenue: Zomedica's total revenue grew significantly by 24.7%, increasing from $6.1 million in 2023 to $7.7 million in 2024. This growth shows increasing demand for their products.
  • Consumables (recurring sales like diagnostics and therapeutics): This segment saw strong growth, rising from $3.1 million in 2023 to $4.8 million in 2024. This highlights robust adoption of their recurring-use products.
  • Capital (equipment sales): This segment also grew, from $2.0 million in 2023 to $2.3 million in 2024.
  • New Engineering Services: A new revenue stream from engineering development services contributed $0.5 million in 2024, diversifying their income.
• Net Loss: Despite revenue growth, Zomedica reported a net loss for 2024. The company continues to operate at an overall loss. This is common for growth-focused companies but requires careful monitoring.
• Market Capitalization: As of June 30, 2024, the total value of Zomedica's publicly traded shares was approximately $38.3 million.

3. Risk Factors

Investors should be aware of these key risks:

• Financial Sustainability: Zomedica's ongoing net losses raise concerns about its ability to achieve profitability and continue operations without raising more capital, which could reduce the value of existing shares.
• Share Dilution: A large number of outstanding shares, plus potential future share issuance from warrants and options, could continue to pressure the stock price per share downwards.
• Intense Competition: Zomedica competes in a crowded animal health market against larger, more established companies with greater resources. This could limit Zomedica's market share and pricing power.
• Product Development & Commercialization: The success of new products and technologies, including those in development (referred to as "Intangible Under Construction"), is not guaranteed. This involves significant research and development (R&D) and regulatory risks.
• Regulatory Environment: The animal health industry faces strict regulations from bodies like the FDA and USDA. Changes in these regulations could impact product approvals, manufacturing, and sales.
• Reliance on Growth Strategy: The company's strategy heavily depends on continued revenue growth and successfully integrating acquisitions. Any slowdown in growth or integration issues could negatively impact investor confidence.
• Economic Factors: Economic conditions affecting discretionary spending on pets could also influence demand for Zomedica's products, posing a risk to revenue.

4. Management Discussion (MD&A Highlights)

Here are the major wins and challenges Zomedica faced this year:

Wins:

• Strong Revenue Growth: A nearly 25% increase in overall revenue is a significant positive, showing market acceptance and traction for their product portfolio.
• Growth in Key Product Areas: Both "consumables" (recurring sales) and "capital" (equipment sales) segments grew, indicating healthy demand across their core offerings.
• New Revenue Stream: The successful launch of engineering services as a new income stream demonstrates strategic diversification.
• Strategic Acquisitions: Past acquisitions, particularly Brisby Inc. and its SmartPetPad, now integrate and contribute to the product lineup and revenue.
• Cresilon Milestones: Achieving sales milestones for Cresilon by the end of 2024 suggests a successful partnership or product line, potentially leading to future payments or continued growth.

Challenges:

• Continued Net Losses: Despite revenue growth, the company still reports net losses. This indicates that operating expenses currently outweigh gross profits, requiring careful cash flow management and future funding.
• Potential Share Dilution: The existence of various outstanding warrants and stock options means the company could issue more shares in the future, potentially reducing the value of existing shares and impacting earnings per share.
• High Operating Expenses: To achieve growth, Zomedica incurs significant R&D and sales & marketing expenses, which contribute to the current net losses.

5. Financial Health

• Shares Outstanding: Zomedica had approximately 980 million shares outstanding as of March 15, 2025. This high share count, combined with the current market capitalization, implies a relatively low stock price per share, which can be a factor for retail investors.
• Equity Compensation: The company issues stock options and Stock Appreciation Rights (SARs) to motivate employees. However, these also represent potential future share dilution or cash payouts.
• Company Classification: The SEC classifies Zomedica as a "Smaller reporting company" and a "Non-accelerated filer." This means Zomedica is not yet a large-cap company and has slightly different, often less stringent, reporting requirements compared to larger public companies.

6. Future Outlook

Zomedica's strategy focuses on aggressive growth through:

• Acquisitions: Integrating companies like Brisby Inc. to expand product lines and market reach.
• Product Development: Investing in new offerings, as indicated by "Intangible Under Construction," which likely refers to ongoing research and development of new intellectual property or products.
• Partnerships: Leveraging collaborations, such as the one with Cresilon, to bring products to market or expand sales channels.

The company aims to become a significant player in the veterinary health space by continuously innovating and expanding its product ecosystem. Zomedica clearly focuses on continued growth, driven by new engineering services, ongoing development of intellectual property, and the successful integration of acquired businesses. The achievement of sales milestones tied to Cresilon suggests a promising product or partnership that could positively impact future performance.

7. Competitive Position

Zomedica actively builds its product portfolio through strategic acquisitions and internal development. They aim to offer a comprehensive suite of diagnostic and therapeutic solutions for veterinarians. Growth in both consumables and capital sales suggests they are gaining traction in their target markets. The new engineering services also indicate an effort to broaden their offerings and potentially differentiate themselves by leveraging their technical expertise. By focusing on specific niches within animal health, such as therapeutic pads and diagnostic platforms, Zomedica carves out a competitive space.